1778-428X/asset/TATM_left.gif?v=1&s=3bd28c9892144a01d500ba5fcdf72aa88665097d)
1778-428X/asset/TATM_right.gif?v=1&s=c2f81ba389f60ee92c612147368cc94980cc275b)
Perioperative use of recombinant activated factor VII in a Jehovah’s Witness patient undergoing sigmoid colectomy
Article first published online: 24 JUL 2006
DOI: 10.1111/j.1778-428X.2006.00003.x
Additional Information
How to Cite
HOLLAND, D. E. and ROBINSON, S. (2006), Perioperative use of recombinant activated factor VII in a Jehovah’s Witness patient undergoing sigmoid colectomy. Transfusion Alternatives in Transfusion Medicine, 8: 14–16. doi: 10.1111/j.1778-428X.2006.00003.x
Publication History
- Issue published online: 24 JUL 2006
- Article first published online: 24 JUL 2006
- Publication data Submitted: 31 August 2004Revision received: 21 March 2005Accepted: 21 March 2005
- Abstract
- Article
- References
- Cited By
Keywords:
- Jehovah’s Witnesses;
- Perioperative hemorrhage;
- Recombinant activated factor VII;
- Rectal bleeding;
- Sigmoid colectomy
SUMMARY
We report the successful use of recombinant activated factor VII (rFVIIa) in a 48-year-old male Jehovah’s Witness with rectal bleeding and perioperative hemorrhage associated with sigmoid colectomy. The patient experienced no further blood loss following the administration of rFVIIa, and no adverse events were observed. Our findings suggest that rFVIIa may represent a new therapeutic opportunity for the management of hemorrhage in patients who do not consent to blood transfusions, and that the use of the agent in this patient population is worthy of further investigation.